Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension

Therapeutic Advances in Cardiovascular Disease

Volumn 4, Issue 4, 2010, Pages 231-240

  Enseleit, Frank ^a   Lüscher, Thomas F ^a   Ruschitzka, Frank ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Darusentan; Endothelin antagonist; HMR 4005; Hypertension; LU 135252

Indexed keywords

BOSENTAN; DARUSENTAN; ENALAPRIL; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; GUANFACINE; PLACEBO;

ANTIHYPERTENSIVE THERAPY; BIOLOGICAL ACTIVITY; BLOOD PRESSURE MONITORING; CARDIOVASCULAR MALFORMATION; CONGESTIVE HEART FAILURE; CRANIOFACIAL MALFORMATION; DIASTOLIC BLOOD PRESSURE; DIET; DIURETIC THERAPY; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FLUID RETENTION; FLUSHING; GLOMERULUS FILTRATION RATE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RATE; HEMOSTASIS; HUMAN; HYPERTENSION; HYPOPLASIA; LIFESTYLE MODIFICATION; MAXIMUM TOLERATED DOSE; MEDLINE; NAUSEA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; NOSE CONGESTION; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINUSITIS; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; THYMUS; TREATMENT DURATION; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; PHENYLPROPIONATES; PYRIMIDINES; RECEPTOR, ENDOTHELIN A; TREATMENT OUTCOME;

EID: 77955351162     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944710373785     Document Type: Article

References (63)

1. Anand, I., McMurray, J., Cohn, J.N., Konstam, M.A., Notter, T., Quitzau, K. et al. (2004) Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364: 347-354.
2. Barton, M., d'Uscio, L.V., Shaw, S., Meyer, P., Moreau, P. and Lüscher, T.F. ( 1998) ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 31: 499-504.
3. Bazil, M.K., Lappe, R.W. and Webb, R.L. ( 1992) Pharmacologic characterization of an endothelinA (ETA) receptor antagonist in conscious rats. J Cardiovasc Pharmacol 20: 940-948.
4. Black, H.R., Bakris, G.L., Weber, M.A., Weiss, R., Shahawy, M.E., Marple, R. et al. (2007) Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 9: 760-769.
5. Boulanger, C. and Lüscher, T.F. ( 1990) Release of endothelin from the porcine aorta. Inhibition of endothelium-derived nitric oxide. J Clin Invest 85: 587-590.
6. Cernacek, P., Franchi, L., Dupuis, J., Rouleau, J.L. and Levy, M. ( 1998) Radioreceptor assay of an endothelin A receptor antagonist in plasma and urine. Clin Chem 44: 1666-1673.
7. Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo Jr, J.L. et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206-1252.
8. Clouthier, D.E., Hosoda, K., Richardson, J.A., Williams, S.C., Yanagisawa, H., Kuwaki, T. et al. (1998) Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development 125: 813-824.
9. Davenport, A.P., O'Reilly, G., Molenaar, P., Maguire, J.J., Kuc, R.E., Sharkey, A. et al. (1993) Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ 123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle. J Cardiovasc Pharmacol 22(Suppl 8): S22-S25.
10. Dhaun, N., Goddard, J. and Webb, D.J. ( 2006) The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 17: 943-955.
11. Dhaun, N., Goddard, J. and Webb, D.J. ( 2010) An endothelin antagonist for resistant hypertension. Lancet 375: 635; author reply 636-637.
12. Dohi, Y., Hahn, A.W., Boulanger, C.M., Bühler, F.R. and Lüscher, T.F. ( 1992) Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 19: 131-137.
13. Dupuis, J. ( 2000) Endothelin receptor antagonists and their developing role in cardiovascular therapeutics. Can J Cardiol 16: 903-910.
14. Enseleit, F., Lüscher, T.F. and Ruschitzka, F. ( 2008) Darusentan: a new perspective for treatment of resistant hypertension?. Expert Opin Investig Drugs 17: 1255-1263.
15. Enseleit, F. and Ruschitzka, F. (2010) Darusentan in resistant hypertension: lost in translation. Curr Hypertens Rep 12: 1-3.
16. Fattinger, K., Funk, C., Pantze, M., Weber, C., Reichen, J., Stieger, B. et al. (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69: 223-231.
17. Gilead Science (2009) Second pivotal phase III study of Gilead's darusentan for resistant hypertension misses primary endpoints. Press release 14 December 2009, Gilead Science. Available at: http://www.gilead.com/pr_1365747.
18. Goddard, J., Johnston, N.R., Hand, M.F., Cumming, A.D., Rabelink, T.J., Rankin, A.J. et al. (2004) Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 109: 1186-1193.
19. Goddard, J. and Webb, D.J. ( 2002) Endothelin antagonists and hypertension: a question of dose? Hypertension 40: e1-2; author reply e1-e2
20. Gregan, B., Schaefer, M., Rosenthal, W. and Oksche, A. ( 2004) Fluorescence resonance energy transfer analysis reveals the existence of endothelin-A and endothelin-B receptor homodimers. J Cardiovasc Pharmacol 44(Suppl 1): S30-S33.
21. Guarda, E., Katwa, L.C., Myers, P.R., Tyagi, S.C. and Weber, K.T. ( 1993) Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 27: 2130-2134.
22. Hosoda, K., Hammer, R.E., Richardson, J.A., Baynash, A.G., Cheung, J.C., Giaid, A. et al. (1994) Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 79: 1267-1276.
23. Janakidevi, K., Fisher, M.A., Del Vecchio, P.J., Tiruppathi, C., Figge, J. and Malik, A.B. ( 1992) Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am J Physiol 263: C1295-C1301.
24. Kiowski, W., Lüscher, T.F., Linder, L. and Bühler, F.R. ( 1991) Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 83: 469-475.
25. Kirkby, N.S., Hadoke, P.W., Bagnall, A.J. and Webb, D.J. ( 2008) The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 153: 1105-1119.
26. Kowala, M.C., Rose, P.M., Stein, P.D., Goller, N., Recce, R., Beyer, S. et al. (1995) Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol 146: 819-826.
27. Krum, H., Viskoper, R.J., Lacourciere, Y., Budde, M. and Charlon, V. ( 1998) The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 338: 784-790.
28. Li, J.S., Knafo, L., Turgeon, A., Garcia, R. and Schiffrin, E.L. ( 1996) Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am J Physiol 271: H88-H93.
29. Li, J.S., Turgeon, A. and Schiffrin, E.L. ( 1998) Effect of chronic treatment with two different ET(A) selective endothelin receptor antagonists on blood pressure and small artery structure of deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Am J Hypertens 11: 554-562.
30. Lüscher, T.F. and Barton, M. ( 2000) Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102: 2434-2440.
31. Lüscher, T.F., Enseleit, F., Pacher, R., Mitrovic, V., Schulze, M.R., Willenbrock, R. et al. (2002) Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 106: 2666-2672.
32. MacLean, M.R., McCulloch, K.M. and Baird, M. ( 1994) Endothelin ETA- and ETB-receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles. J Cardiovasc Pharmacol 23: 838-845.
33. Mancia, G., de Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G. et al. (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28: 1462-1536.
34. Motte, S., McEntee, K. and Naeije, R. ( 2006) Endothelin receptor antagonists. Pharmacol Ther 110: 386-414.
35. Nakov, R., Pfarr, E. and Eberle, S. ( 2002) Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens 15: 583-589.
36. Neuhofer, W. and Pittrow, D. (2009) Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence. Eur J Clin Invest 39(Suppl 2): 50-67.
37. Ogawa, Y., Nakao, K., Arai, H., Nakagawa, O., Hosoda, K., Suga, S. et al. (1991) Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biochem Biophys Res Commun 178: 248-255.
38. Opitz, C.F., Ewert, R., Kirch, W. and Pittrow, D. ( 2008) Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J 29: 1936-1948.
39. Packer, M. ( 2002) Late breaking clinical trials II. Effects of the endothelin receptor antagonist bosentan on the morbitity and mortality in patients with chronic heart failure. Results of the ENABLE 1 and 2 trial program. American College of Cardiology 51st Annual Scientific Sessions 2002, American College of Cardiology: Atlanta, GA.
40. Packer, M., Caspi, A., Charlon, V., La Roche, H., Cohen-Solal, A., Kiowski, W. et al. (1998) Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure - Results of the REACH-1 trial. Circulation 98(Suppl): S12.
41. Plato, C.F. and Garvin, J.L. ( 1999) Nitric oxide, endothelin and nephron transport: potential interactions. Clin Exp Pharmacol Physiol 26: 262-268.
42. Prasad, V.S., Palaniswamy, C. and Frishman, W.H. (2009) Endothelin as a clinical target in the treatment of systemic hypertension. Cardiol Rev 17: 181-191.
43. Raschack, M., Unger, L., Riechers, H. and Klinge, D. ( 1995) Receptor selectivity of endothelin antagonists and prevention of vasoconstriction and endothelin-induced sudden death. J Cardiovasc Pharmacol 26(Suppl 3): S397-S399.
44. Ruetten, H. and Thiemermann, C. ( 1997) Endothelin-1 stimulates the biosynthesis of tumour necrosis factor in macrophages: ET-receptors, signal transduction and inhibition by dexamethasone. J Physiol Pharmacol 48: 675-688.
45. Ruschitzka, F., Quaschning, T., Noll, G., deGottardi, A., Rossier, M.F., Enseleit, F. et al. (2001) Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide. Circulation 103: 3129-3135.
46. Saito, Y., Nakao, K., Mukoyama, M. and Imura, H. ( 1990) Increased plasma endothelin level in patients with essential hypertension. N Engl J Med 322: 205.
47. Schiffrin, E.L., Lariviere, R., Li, J.S., Sventek, P. and Touyz, R.M. ( 1995a) Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension 25: 769-773.
48. Schiffrin, E.L., Sventek, P., Li, J.S., Turgeon, A. and Reudelhuber, T. ( 1995b) Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats. Br J Pharmacol 115: 1377-1381.
49. Schneider, J.G., Tilly, N., Hierl, T., Sommer, U., Hamann, A., Dugi, K. et al. (2002) Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens 15: 967-972.
50. Schrader, J., Tebbe, U., Borries, M., Ruschitzka, F., Schoel, G., Kandt, M. et al. (1990) [Plasma endothelin in normal probands and patients with nephrologicrheumatologic and cardiovascular diseases]. Klin Wochenschr 68: 774-779.
51. Seo, B., Oemar, B.S., Siebenmann, R., von Segesser, L. and Lüscher, T.F. ( 1994) Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 89: 1203-1208.
52. Simonson, M.S. and Dunn, M.J. ( 1990) Cellular signaling by peptides of the endothelin gene family. FASEB J 4: 2989-3000.
53. Spieker, L.E., Mitrovic, V., Noll, G., Pacher, R., Schulze, M.R., Muntwyler, J. et al. (2000) Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators. J Am Coll Cardiol 35: 1745-1752.
54. Sütsch, G., Kiowski, W., Yan, X.W., Hunziker, P., Christen, S., Strobel, W. et al. (1998) Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 98: 2262-2268.
55. Sventek, P., Turgeon, A., Garcia, R. and Schiffrin, E.L. ( 1996) Vascular and cardiac overexpression of endothelin-1 gene in one-kidney, one clip Goldblatt hypertensive rats but only in the late phase of two-kidney one clip Goldblatt hypertension. J Hypertens 14: 57-64.
56. The Lancet (2007) Hypertension: uncontrolled and conquering the world. Lancet 370: 539.
57. Treinen, K.A., Louden, C., Dennis, M.J. and Wier, P.J. ( 1999) Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits. Teratology 59: 51-59.
58. Watts, S.W. (2010) Endothelin receptors: what's new and what do we need to know?. Am J Physiol Regul Integr Comp Physiol 298: R254-R260.
59. Weber, M.A., Black, H., Bakris, G., Krum, H., Linas, S., Weiss, R. et al. (2009) A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374: 1423-1431.
60. Williams, B. (2009) Resistant hypertension: an unmet treatment need. Lancet 374: 1396-1398.
61. Wilson, D.I., Burn, J., Scambler, P. and Goodship, J. ( 1993) DiGeorge syndrome: part of CATCH 22. J Med Genet 30: 852-856.
62. Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y. et al. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415.
63. Yang, Z., Krasnici, N. and Lüscher, T.F. ( 1999) Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation 100: 5-8.